Kimberly-Clark prepares asset divestitures to secure EU approval for $40 billion Kenvue acquisition
U.S. consumer goods company Kimberly-Clark is preparing to divest assets to secure European Union regulatory approval for its planned $40 billion acquisition of Kenvue, a consumer health business spun off from Johnson & Johnson. The preemptive move addresses potential antitrust concerns from the European Commission, with a September 29 deadline to avoid a longer investigation. Similar conditional approval was granted in Australia after divesting certain brands. The deal would create a combined company with about $32 billion in annual revenue.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Kimberly-Clark Prepares Asset Sales to Address EU Antitrust Concerns Over Kenvue Deal
Kimberly-Clark Corporation is preparing asset sales to address EU antitrust concerns regarding its planned $40 billion acquisition of Kenvue, according to a Reuters report cited by Yahoo Finance. The company seeks to offer remedies to secure European Commission approval by the September 29 deadline, avoiding a more extensive four-month investigation. Similar regulatory concerns emerged in Australia, where the deal received conditional approval after Kimberly-Clark agreed to divest Kenvue's Carefree and Stayfree brands. The transaction would create a consumer-health and personal-care company with approximately $32 billion of annual revenue and $7 billion of adjusted EBITDA. Kimberly-Clark expects about $1.9 billion of annual cost synergies and $500 million of revenue synergies, though it plans to invest roughly $2.5 billion in cash to achieve cost savings. The article presents a cautiously bullish view, noting that limited asset sales could preserve most of Kenvue's earnings while avoiding a prolonged regulatory process. Risks include the EU requiring more substantial divestitures, which could reduce the deal's attractiveness, and potential delays postponing synergy benefits while costs accumulate.
Kimberly-Clark shares rise 2% on report of asset sales to secure EU approval for Kenvue deal
Kimberly-Clark shares rose approximately 2% following a Reuters report, citing unnamed sources, that the company is preparing to sell assets in order to secure European Union regulatory approval for its planned acquisition of Kenvue. The report suggests that the asset sales are a preemptive measure to address potential antitrust concerns from EU competition authorities. The stock price increase reflects investor optimism that the company is taking proactive steps to facilitate the deal's clearance. The acquisition of Kenvue, a consumer health company, would expand Kimberly-Clark's portfolio. The exact assets to be divested and the timeline for the sale remain unclear, as the information is based on anonymous sources. The EU approval process is a key regulatory hurdle for the transaction.
Read sourceKimberly-Clark to Divest Assets for EU Approval of $40 Billion Kenvue Deal
According to sources cited by Cailian Press on September 14, U.S. personal care and hygiene products giant Kimberly-Clark is preparing to divest certain assets. This move is intended to secure approval from the European Union for its proposed $40 billion acquisition of Kenvue, a consumer health company. The report indicates that the divestiture is a strategic step to address potential antitrust concerns from EU regulators regarding the large-scale merger. The deal, if completed, would significantly expand Kimberly-Clark's footprint in the consumer health sector. The information is attributed to unnamed sources familiar with the matter, and the outcome of the EU review remains uncertain pending the formal submission of the divestment plan.
Show 2 older updatesHide older updates
Kimberly-Clark to Divest Assets for EU Approval of $40 Billion Kenvue Deal: Sources
According to sources cited by Reuters and reported by TradeAlpha, U.S. consumer goods company Kimberly-Clark is preparing to divest certain assets in order to secure approval from the European Union for its proposed $40 billion acquisition of Kenvue. The move is a preemptive step to address potential antitrust concerns from EU regulators regarding the large-scale merger. The report indicates that the divestiture plan is part of Kimberly-Clark's strategy to gain regulatory clearance for the transaction, which would combine two major players in the consumer health and hygiene sectors. The outcome of the EU review remains uncertain, and the specific assets to be sold have not been disclosed.
Read sourceKimberly-Clark prepares asset divestitures for EU approval of $40 billion Kenvue acquisition
According to Reuters sources, U.S. consumer goods company Kimberly-Clark is preparing to divest assets in order to secure European Union regulatory approval for its planned $40 billion acquisition of Kenvue. The report, attributed to unnamed sources, indicates that the company is taking proactive steps to address potential antitrust concerns from EU regulators. The acquisition of Kenvue, a consumer health business spun off from Johnson & Johnson, would significantly expand Kimberly-Clark's portfolio. The asset divestitures are seen as a strategic move to alleviate competition concerns in relevant markets. The deal's approval is contingent on the European Commission's review, and the outcome remains uncertain pending further regulatory proceedings.
Read source